Brief Summary of Prescribing Information.
Consult Full Prescribing Information at REVATIOHCP.com
INDICATION AND USAGE
REVATIO is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in
adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening
was demonstrated when REVATIO was added to background epoprostenol therapy.
Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately
patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic
etiology (71%) or associated with connective tissue disease (CTD) (25%).
Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect
on exercise capacity.
DOSAGE AND ADMINISTRATION
REVATIO Tablets and Oral Suspension The recommended dose of REVATIO is 5 mg or 20 mg
three times a day. Administer REVATIO doses 4–6 hours apart. In the clinical trial no greater
efficacy was achieved with the W6R